Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Incyte
Pharma
Incyte's Opzelura scores in hidradenitis suppurativa study
The company presented positive data from a phase 2 study in mild-to-moderate hidradenitis suppurativa at the AAD's annual meeting on Sunday.
Zoey Becker
Mar 11, 2024 1:58pm
Incyte turns to AI to illustrate the unseen symptoms of MPNs
Mar 5, 2024 12:00pm
Amid GSK showdown, Incyte crosses $1B in quarterly revenue
Feb 13, 2024 11:05am
Incyte picks up full Monjuvi rights from MorphoSys for $25M
Feb 6, 2024 9:59am
Novartis eyes MorphoSys buyout: Reuters
Feb 5, 2024 3:39pm
Leo Pharma builds its case for JAK inhibitor cream delgocitinib
Jan 24, 2024 10:36am